This message was sent to ##Email##
The application deadline is January 7, 2018.
The National Council of the AFMR invites you to apply for the following AFMR National Awards. Recipients will present their work during an oral session at the 2018 Translational Science meeting to be held April 19-21, 2018 in Washington, DC.
AFMR Eastern Regional Meeting
March 16, 2018 | Wyndham Philadelphia Historic District | Pennsylvania
Submit your late breaking abstract for an oral or poster presentation in a supportive meeting with leaders in medical research. Join us in Philly this year!
- Late Breaking Abstracts Submission Deadline: Sunday, January 7, 2018 at 11:59 pm ET
- Receive notification by January 22, 2018
- Accepted abstracts eligible for Eastern Regional Scholar Awards
*Register before the February 5, 2018 discounted registration deadline*
Western Medical Research Conference Registration
Early Bird Deadline: Thursday, January 11, 2018
The 2018 Western Medical Research Conference (WMRC) take place at the Sunset Center in Carmel. Since there is no Hotel Headquarters, the Western societies have arranged to use a reservation service that will assist you with your hotel, motel, and inn accommodations for the "Doctor’s Meeting", some special rates are being held. Please contact any of the following: (there is no fee for booking).
Student and Resident Hotel Reservations:
All students stay at the Carmel Mission Inn. Please use group code: "WSMRF" when making reservations. To make a reservation call: 1-800-348-9090; cut-off January 10, 2018 by 6:00 pm. Online reservations are not available for this group discount. You must call the hotel.
Collaborate with the leading scientists on emerging and cutting-edge research and topics in your field.
FASEB’s Scientific Research Conferences connect experts and early career professionals in collaborative/interactive environments packed with lectures, posters sessions, career workshops, and networking.
Click on the 2018 conferences below to learn about program highlight and add the event dates to your calendar. Registration will open on Thursday, January 11, 2018!
FASEB seeks applications for the position of Editor-in-Chief (EIC). The EIC position will be for a new open access journal. The ideal candidate will be a distinguished scientist with a Ph.D., M.D., or an equivalent academic degree, experience in experimental biological and biomedical sciences, and prior experience in editorial activities related to scholarly journals. The initial term will be three years, but may be renewed if mutually agreed by FASEB and the selected candidate. The EIC will have responsibility for establishing editorial workflows and selecting supporting editors and an editorial board. It is a volunteer position that reports to FASEB’s Board of Directors through the FASEB Publications and Communications Committee. The position will remain open until a suitable candidate has been identified and the vacancy filled.
Bone marrow near paralyzed muscles rapidly becomes inflamed. Muscle paralysis rapidly causes inflammation in nearby bone marrow, which may promote the formation of large cells that break down bone, a new study finds. The article is published in the American Journal of Physiology—Cell Physiology.
The stopgap spending bill approved by Congress is a temporary fix to keep our government running but presents an ongoing challenge in ensuring our nation’s scientific enterprise has robust federal support to advance innovative research. Once again our elected officials have punted on decisions regarding spending levels for defense and non-defense programs, creating uncertainty for federal health and science agencies at a time when immediate actions are necessary to address major health threats including the opioid epidemic.
Deregulated profiles of urinary microRNAs may explain podocyte injury and proximal tubule dysfunction in normoalbuminuric patients with type 2 diabetes mellitus
Oana Milas, Florica Gadalean, Adrian Vlad, Victor Dumitrascu, Cristina Gluhovschi, Gheorghe Gluhovschi, Silvia Velciov, Roxana Popescu, Flaviu Bob, Petru Matusz, Agneta-Maria Pusztai, Octavian M Cretu, Alina Secara, Anca Simulescu, SorinUrsoniu, Daliborca Vlad, Ligia Petrica
Journal of Investigative Medicine Dec 2017, jim-2017-000556; DOI: 10.1136/jim-2017-000556
Thromboembolismpeaking 3 months after starting testosterone therapy: testosterone–thrombophilia interactions
Charles J Glueck, Naila Goldenberg, Ping Wang
Journal of Investigative Medicine Dec 2017, jim-2017-000637; DOI: 10.1136/jim-2017-000637
Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins
Arun Sanyal, Kenneth Cusi, Mark L Hartman, Shuyu Zhang, Edward J Bastyr, Juliana M Bue-Valleskey, Annette M Chang, Axel Haupt, Scott J Jacober, Robert J Konrad, Qianyi Zhang, Byron J Hoogwerf
Journal of Investigative Medicine Nov 2017, jim-2017-000609; DOI: 10.1136/jim-2017-000609
Impact of weight loss on inflammation and red blood cell biomarkers after laparoscopic gastric banding surgery
Susana Coimbra, Cátia Ferreira, Luís Belo, Petronila Rocha-Pereira, Alice Catarino, Luís Monteiro, Cristina Catarino, AliceSantos-Silva
Journal of Investigative Medicine Nov 2017, jim-2017-000528; DOI: 10.1136/jim-2017-000528
Propranolol-Induced Circulatory Collapse in a Patient With Thyroid Crisis and Underlying Thyrocardiac Disease: A Word of Caution
Michael McPhaul, MD,
Thyrotoxic crisis or thyroid storm is a severe form of hyperthyroidism and a rare endocrinological emergency. The cornerstones of medical therapy in thyroid storm include decreasing the levels of circulating T3 in the blood as well as inhibiting the hormone’s peripheral effects through β-adrenergic blockade. Propranolol is the preferred agent for β-blockade in hyperthyroidism and thyroid storm due to its additional effect of blocking the peripheral conversion of inactive T4 to active form T3. We report a typical clinical scenario where propranolol was administered in treatment of thyroid storm but an uncommon adverse outcome: circulatory failure from cardiogenic shock warranting vasopressor and inotropic support. Caution with regard to the use long-acting β-blocking agents in patients with underling thyrocardiac disease may prevent this life-threatening adverse effect. Ultra–short-acting β-blockers that are easy to titrate maybe a suitable alternative in this subset of patients. READ MORE
Mixed Adenoneuroendocrine Carcinoma of the Gastroesophageal Junction: A Rare Find
Neoplastic lesions that demonstrate neuroendocrine features are rare. However, esophageal tumors containing both adenocarcinomatous and neuroendocrine components are exceedingly rare. Mixed adenoneuroendocrine carcinomas (MANECs) are gastrointestinal tumors with both adenocarcinomatous and neuroendocrine differentiation. They have a tendency for early metastases but clinically manifest relatively late. Imaging studies are often nonspecific with regard to tumor type, and a histopathologic study of biopsy material is required for definitive diagnosis. The overall prognosis is poor. The current report describes a rare case of gastroesophageal MANEC tumor, with approximately 60% neuroendocrine and 40% adenocarcinomatous components. Since there is a dearth of concrete management guidelines for MANECs, we present possible management options to add to the existing literature. READ MORE
Stay informed about JIM-HICR and register for e-alerts.
A drug developed for type 2 diabetes has "significantly reversed memory loss" in mice with Alzheimer's disease, and researchers now want to test it on humans. The treatment is exciting for scientists because it works by protecting the brain cells attacked by Alzheimer's disease in three separate ways, rather than relying on a single approach.
Clinical Oncology News
Results from ProfilER-01, one of the largest clinical trials assessing high-throughput genomic analyses for a large variety of cancers, demonstrated that routine genomic testing is feasible in a local and regional setting in France. The second phase of the trial is ongoing and will evaluate whether a larger gene panel leads to more targeted therapy recommendations. “Comprehensive genomic profiling can be performed in routine practice to select patients for targeted cancer therapies,” reported investigator Olivier Trédan, MD, PhD.
A noninvasive brainwave mirroring technology significantly reduced symptoms of post-traumatic stress in military personnel in a pilot study conducted at Wake Forest Baptist Medical Center. The study is published in the Dec. 22 online edition of the journal Military Medical Research. "Ongoing symptoms of post-traumatic stress, whether clinically diagnosed or not, are a pervasive problem in the military," said the study's principal investigator, Charles H. Tegeler, M.D., professor of neurology at Wake Forest School of Medicine, a part of Wake Forest Baptist.
Specialty Pharmacy Times
Nanoparticles have been a promising drug delivery method for various forms of cancer and other diseases that require a highly-targeted therapy. Delivering a combination of cancer drugs via a targeted nanoparticle may provide a more potent treatment against a deadly form of endometrial cancer, according to a study published by Nature Nanotechnology. In the study, chemotherapy and a drug that combats drug-resistant cells were loaded into nanoparticles in an attempt to create a highly-effective approach to treating cancer.
|January 25-27, 2018
||Western Medical Research Conference
|February 22-24, 2018
||Southern Regional Meeting
||New Orleans, LA
|March 16, 2018
||Eastern Regional Meeting
|April 19-21, 2018
||Translational Science 2018
|April 21-25, 2018
|| Experimental Biology 2018
||San Diego, CA
|April 26-27, 2018
||2018 Combined Annual Meeting of CSCTR & MWAFMR
| || |
Connect with AFMR
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Natalie Thomas, Assistant Executive Editor, 469-420-2635 | Contribute news
MingMing Ning, AFMR Chair, Publishing Committee, 978-927-8330 | www.afmr.org
Elissa Klein, AFMR Executive Director, 978-927-8330 | www.afmr.org
American Federation for Medical Research
500 Cummings Center, Suite 4400 | Beverly, MA 01915 | 978-927-8330 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063